<DOC>
	<DOCNO>NCT00809731</DOCNO>
	<brief_summary>The objective study evaluate routine clinical set efficacy remission status treatment 2nd-generation antipsychotic patient upon acute episode achieve remission regular treatment schizophrenia/schizoaffective disorder . This study collect real-life practice severity schizophrenia Clinical Global Impression ( CGI ) , also evaluate criterion schizophrenia remission apply 8 item Positive Negative Syndrome Scale ( PANSS ) Andresen work group , Montgomery Asberg Depression Rating Scale ( MADRS ) , Global Assessment Functioning Scale ( GAF ) . Side effect movement disorder evaluate Drug Induced Extrapyramidal Symptoms Scale ( DIEPSS ) . Tolerability treatment monitor document spontaneous report adverse event well change body weight .</brief_summary>
	<brief_title>Observational Study Evaluate Efficacy Remission Status Schizophrenia Patients Under Atypical Treatment</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients acute episode ( first relapse ) , upon revisit identify achieve remission schizophrenia schizoaffective disorder ( accord remission criterion schizophrenia ) Male female age 18 65 year Patients recruit inpatient outpatient clinic Patients cooperative , judgment investigator , use oral antipsychotic consider adequate Pregnancy lactation Patients , opinion investigator , pose imminent risk suicide danger self others Known intolerance , lack response , contraindication prescribe atypical antipsychotic , judged investigator Administration depot antipsychotic injection within one dose interval ( depot ) enrolment patient prescribed clozapine within 3 month prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Schizophrenia remission status 8-item PANSS</keyword>
</DOC>